It also mimics the inflammatory events associated with in vivo epilepsy and allows to interfere pharmacologically with inflammatory pathways, such as the NLRP3 inflammasome signaling, before and after the onset of epileptic-like events, prompting the screening of potential targets for antiepileptic drugs. Here, NLRP3 is linked to epilepsy.